Abstract
Capmatinib (Tabrecta (TM)) is an oral, small molecule mesenchymal-epithelial transition (MET) inhibitor being developed by Novartis Oncology, under a ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
